evoke semaglutide trial Efficacy and safety of oral 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials Phase 3 Trial of Semaglutide

In addition, the older age group in SUSTAIN 6 included both those with established CVD and those with CV risk factors alone, while the younger group of subjects included only those with established CVD

PubMed laboratory research record [PMID: 5538751] PubMed record related to this compound for laboratory literature review

Domperidone and metoclopramide have MHRA restrictions due to cardiac and neurological risks respectively, and should be used at the lowest effective dose for the shortest duration

**Interference with Chemotherapy**: There is some evidence to suggest that glutathione may interfere with certain chemotherapy drugs